top of page

MHRA's New & updated Innovative Licensing and Access Pathway - UK

Writer's picture: Sharan MuruganSharan Murugan

A new pathway supporting innovative approaches to the safe, timely, and efficient development of medicines to improve patient access was updated on 23rd August 2021.

The Innovative Licensing and Access Pathway (ILAP) intends to accelerate the time to market, facilitating patient access to medicines. These medicines include new chemical entities, biological medicines, new indications, and repurposed medicines.


The ILAP is open to both commercial and non-commercial developers of medicines (UK-based and or global). It comprises of an Innovation Passport designation, a Target Development Profile (TDP) and provides applicants with access to a toolkit to support all stages of the design, development, and approvals process.


The permanent partners in the ILAP are:

  • The Medicines and Healthcare products Regulatory Agency (MHRA)

  • National Institute for Health and Care Excellence (NICE)

  • Scottish Medicines Consortium (SMC)

Supporting partners include:

  • NHS England and NHS Improvement

  • Health Research Authority (HRA)

  • National Institute for Health Research (NIHR)

Check out More details on ILAP here.

35 views0 comments

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page